ACR 2026 data show 56.7% of patients with PsA met GLP-1 RA eligibility criteria, but only 15.7% were prescribed treatment.
|Articles|May 6, 2021
Rheumatology Network's Spotlight: Clinical Updates in Psoriatic Arthritis
Author(s)Lana Pine
Catch up on Rheumatology Network's most recent highlights in psoriatic arthritis news.
Advertisement
Advertisement
Related to this article
The FDA approved tildrakizumab for adults with active psoriatic arthritis based on two phase 3 trials showing improved ACR20 response at week 24 vs placebo.
On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for PsA.
In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
Advertisement
Advertisement
Trending on Rheumatology Live
1
Retatrutide Cuts Knee OA Pain, With Philip Conaghan, MBBS, PhD
2
Bimekizumab Leads New Wave of PsA Comparative Data: Philip Mease, MD
3
CD19 CAR T Shows Early Remission in Treatment-Refractory RA
4
Adding Tirzepatide Improves PsA Control in Obesity: Philip Mease, MD
5